natgillin/translations-raw huggingface dataset:
In addition, field data were presented comparing the clinical outcome in pigs with respiratory disease on farms where APP and P.multocida are simultaneously present, and which have been vaccinated with either APPM Respipharm or a competitor product incorporating APP only.
Poleg tega so bili predloženi terenski podatki za primerjavo kliničnega izida pri prašičih z boleznijo dihal na kmetijah, kjer sta bila sočasno prisotna APP in P. multocida, in prašičih, ki so bili cepljeni bodisi s cepivom APPM Respipharm ali konkurenčnim cepivom, ki vsebuje le APP.
The justification to include the P.multocida component in the vaccine had been accepted by the Committee during the referral procedure.
Odbor je med napotitvenim postopkom sprejel utemeljitev vključitve komponente P. multocida v cepivo.
In addition, field data have been accumulated comparing the clinical outcome in pigs with respiratory disease on farms where APP and P.multocida are simultaneously present, and which have been vaccinated with either APPM Respipharm or a competitor product incorporating APP only.
Poleg tega so bili zbrani terenski podatki za primerjavo kliničnega izida pri prašičih z boleznijo dihal na kmetijah, kjer sta bila sočasno prisotna APP in P. multocida, in prašičih, ki so bili cepljeni bodisi s cepivom APPM Respipharm ali konkurenčnim cepivom, ki vsebuje le APP.
The Note for Guidance on requirements for combined veterinary vaccines2, states “Deletion of challenges is only acceptable in rare cases and must be fully justified.”, and in addition Annex I to Directive 2001/82/EC as amended (Part 4 Efficacy tests, Field trials), which states that “Where laboratory trials cannot be supportive of efficacy, the performance of field trials alone may be acceptable.”.
Poleg tega pa Dodatek I k Direktivi 2001/82/ES, kakor je bila spremenjena (4. del: Preskusi učinkovitosti, Preskušanja na terenu), določa naslednje: „Če laboratorijski preskusi ne dokazujejo učinkovitosti, je lahko sprejemljiva tudi samo izvedba terenskih preskušanj.“.
The potency test for P. multocida should be able to distinguish potent and subpotent batches.
Preskus učinkovitosti za komponento P. multocida mora dokazati razlike med serijami s primerno in manj primerno učinkovitostjo.
Pregnant sows:
Breje svinje:
Booster: One injection 2-3 weeks before each farrowing.
Poživitveni odmerek: eno injiciranje 2-3 tedne pred pričakovano kotitvijo
GROUNDS FOR REFUSAL OF THE GRANTING OF THE MARKETING AUTHORISATIONS SUSPENSION OF THE MARKETING AUTHORISATION
PODLAGA ZA ZAVRNITEV ODOBRITVE DOVOLJENJ ZA PROMET Z ZDRAVILOM IN ZADRŽANJE DOVOLJENJA ZA PROMET Z ZDRAVILOM
The lack of convincing data in support of the efficacy of P.multocida was considered a particular weakness.
Za posebno slabost se je štelo pomanjkanje prepričljivih podatkov v podporo učinkovitosti komponente P. multocida.
There are two points for particular discussion, firstly that challenge has not been done with APP Serotype 11, and secondly that because efficacy of the P.multocida component is based principally on field data there are no information on the precise specifications of the batches used.
Drugič, ker učinkovitost komponente P. multocida v glavnem temelji na terenskih podatkih, ni podatkov o natančnih specifikacijah za uporabljene serije.
The frequency of isolations of each organism in unvaccinated pigs provided some indication of the prevalence of the agent at the site and, taken in association with experience of pathology, could be considered to provide some support for the classification process.
Pogostnost osamitev posameznega organizma pri necepljenih prašičih do neke mere kaže lokalno pogostnost povzročitelja.
This was in part supported by the view that since P.multocida is a secondary infection that any possible benefits seen could equally well be attributed to a reduction of incidence of disease caused by the primary agent (A.pleuropneumoniae) afforded by vaccination against APP.
To delno podpira mnenje, da je P. multocida povzročitelj sekundarnih okužb in bi se lahko vsi možni koristni učinki enako verjetno pripisali zmanjšanju pojavnosti bolezni, povzročene s primarnim povzročiteljem (A. pleuropneumoniae), ki jo zagotovimo s cepljenjem proti APP. Glede na ta dejstva je Odbor zaključil, da učinkovitost komponente P. multocida serotipa A ni bila zadostno dokazana, zato mora biti v odsotnosti dokazanih koristi vsaka analiza tveganja in koristnih učinkov obvezno negativna.
First injection 4-5 weeks before expected farrowing.
Prvo injiciranje 4-5 tednov pred pričakovano kotitvijo Drugo injiciranje najmanj 2 tedna pred pričakovano kotitvijo
Slovak
Poljska
Strains of Actinobacillus pleuropneumoniae producing Apx I, ApxII and ApxIII toxins:
Sevi Actinobacillus pleuropneumoniae, ki tvorijo toksine Apx I, ApxII in ApxIII: Actinobacillus pleuropneumoniae serotip 2 ≥ 4'8 log2 (*)
Date of first authorisation: 11 November 2013 Date of latest renewal: 8 June 2018
Datum prve odobritve: 11. november 2013 Datum zadnjega podaljšanja: 8. junij 2018
Experience with Corbilta in patients under 18 years is limited.
Izkušnje z zdravilom Corbilta pri bolnikih, starih manj kot 18 let, so omejene.
You should be aware that Corbilta may make these reactions worse.
Zavedati se morate, da lahko zdravilo Corbilta te reakcije še poslabša.
Your doctor may take some regular laboratory tests during a long term treatment with Corbilta.
Zdravnik lahko izvede nekaj rednih laboratorijskih preiskav med dolgoročnim zdravljenjem z zdravilom Corbilta.
Paediatric population: The safety and efficacy of Corbilta in children aged below 18 years have not been established.
Pediatrična populacija: Varnost in učinkovitost zdravila Corbilta pri otrocih starih do 18 let nista bili dokazani.
Therefore, do not take Corbilta and iron supplements at the same time.
Zato ne jemljite zdravila Corbilta in železovih dodatkov sočasno.
However, caution should be exercised when these medicinal products are used concomitantly with Corbilta (see sections 4.3 and 4.4).
Vseeno pa je potrebna previdnost, kadar se ta zdravila uporabljajo sočasno z zdravilom Corbilta (glejte poglavji 4.3 in 4.4).
Corbilta should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.
Zdravila Corbilta ne smete uporabljati pri nosečnicah, razen če koristi za mater ne odtehtajo morebitnega tveganja za plod.
The starting dose of Corbilta should provide either the same amount of levodopa or slightly (5-10%) more.
Začetni odmerek zdravila Corbilta naj zagotavlja enako ali nekoliko (5-10 %) večjo količino levodope.
The CHMP agrees with the scientific conclusions made by the PRAC.The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP se strinja z znanstvenimi zaključki odbora PRAC.
For some patients, Corbilta may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts).
Pri nekaterih bolnikih se zdravilo Corbilta ne absorbira tako dobro, če ga jemljejo med obrokom ali kmalu po obroku proteinsko bogate hrane (npr. meso, ribe, mlečni izdelki, semena in oreški).
Other medicines and Corbilta
Druga zdravila in zdravilo Corbilta
If you must undergo surgery, please tell your doctor that you are using Corbilta.
Če morate na operacijo, povejte svojemu zdravniku, da jemljete zdravilo Corbilta.
Corbilta with food and drink
Zdravilo Corbilta skupaj s hrano in pijačo
Corbilta may have a major influence on the ability to drive and use machines.
Zdravilo Corbilta ima pomemben vpliv na sposobnost vožnje in upravljanja strojev.
- All patients treated with Corbilta should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.
- Vse bolnike, ki se zdravijo z zdravilom Corbilta, je treba skrbno spremljati, če bi prišlo do psihičnih sprememb, depresije s samomorilnimi nagnjenji ter drugih resnih oblik antisocialnega vedenja.
What Corbilta is and what it is used for
Kaj je zdravilo Corbilta in za kaj ga uporabljamo
Corbilta may lower your blood pressure, which may make you feel light-headed or dizzy.
Zdravilo Corbilta lahko zniža vaš krvni tlak, zaradi česar se boste počutili vrtoglavi in omotični.
In the pharmacokinetic studies with Corbilta the bioavailability of levodopa is higher in women than in men, primarily due to the difference in body weight, while there is no gender difference with carbidopa and entacapone.
V raziskavah farmakokinetike zdravila Corbilta je biološka uporabnost levodope pri ženskah večja kot pri moških predvsem zaradi razlike v telesni masi, medtem ko pri karbidopi in entakaponu razlike med spoloma ni bilo.
What you need to know before you take Corbilta
Kaj morate vedeti, preden boste vzeli zdravilo Corbilta
5 How to store Corbilta Contents of the pack and other information
5 Shranjevanje zdravila Corbilta Vsebina pakiranja in dodatne informacije
When used with Corbilta, the daily dose of selegiline should not exceed 10 mg.
Ob sočasni uporabi z zdravilom Corbilta skupni dnevni odmerek selegilina ne sme presegati 10 mg.
If you have accidentally taken more Corbilta tablets than you should, talk to your doctor or pharmacist immediately.
Če ste po naključju vzeli več tablet zdravila Corbilta, kot bi smeli, se nemudoma posvetujte s svojim zdravnikom ali farmacevtom.
Therefore, the use of Corbilta in children or adolescents is not recommended.
Zato se uporaba zdravila Corbilta pri otrocih ali mladostnikih ne priporoča.
- Corbilta contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
- Zdravilo Corbilta vsebuje saharozo, zato bolniki z redkimi prirojenimi motnjami, kot so intoleranca za fruktozo, malabsorpcija glukoze-galaktoze ali pomanjkanje saharaze-izomaltaze, ne smejo jemati tega zdravila.
Do not take Corbilta if you are taking certain medicines for treating depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).
Ne uporabljajte zdravila Corbilta, če jemljete nekatera zdravila za zdravljenje depresije (kombinacija selektivnih zaviralcev MAO-A in MAO-B ali neselektivnih zaviralcev MAO).
Corbilta is used for the treatment of Parkinson's disease.
Zdravilo Corbilta se uporablja za zdravljenje Parkinsonove bolezni.
What Corbilta is and what it is used for What you need to know before you take Corbilta How to take Corbilta
Kaj je zdravilo Corbilta in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Corbilta Kako jemati zdravilo Corbilta Možni neželeni učinki
Pyridoxine, however, is not effective in reversing the actions of Corbilta.
Vendar pa piridoksin ni učinkovit kot protisredstvo za delovanje zdravila Corbilta.
- Corbilta is not recommended for the treatment of drug-induced extrapyramidal reactions.
- Zdravilo Corbilta se ne priporoča za zdravljenje ekstrapiramidnih reakcij, ki jih povzročajo zdravila.
- If general anaesthesia is required, therapy with Corbilta may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth.
- Če je potrebna splošna anestezija, se lahko terapija z zdravilom Corbilta nadaljuje vse dokler sme bolnik jemati tekočine in zdravila peroralno.
It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Corbilta treatment.
Zato bo morda potrebno v prvih dneh oziroma prvih tednih po uvedbi zdravljenja z zdravilom Corbilta, zlasti pri bolnikih z diskinezijo zmanjšati odmerek levodope za 10-30 %.
Corbilta may increase the effects and side effects of certain medicines.
Zdravilo Corbilta lahko poveča učinke in neželene učinke določenih zdravil.
Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Corbilta may be impaired in some patients on high protein diet.
Druge oblike interakcij: Ker levodopa tekmuje (kompetitira) z nekaterimi aminokislinami, je lahko pri nekaterih bolnikih, ki uživajo visoko proteinsko dieto, absorpcija zdravila Corbilta motena.
Therefore, Corbilta and iron preparations should be taken at least 2-3 hours apart (see section 4.8).
Zato je treba pri jemanju zdravila Corbilta in železovih pripravkov upoštevati najmanj 2-3 urni razmak med obema zdraviloma (glejte poglavje 4.8).
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Corbilta therapy.
Drugi antiparkinsoniki: Do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila Corbilta.
Corbilta contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet.
Zdravilo Corbilta vsebuje tri učinkovine (levodopo, kabidopo in entakapon) v eni filmsko obloženi tableti.
Tell your doctor if you or your family/carer notices you are developing addiction-like symptoms leading to craving for large doses of Corbilta and other medicines used to treat Parkinson's disease.
Obvestite zdravnika, če vi ali kdo od družinskih članov/negovalec opazi(te), da se pri vas razvijajo simptomi, podobni odvisnosti, ki vodijo do potrebe po velikih odmerkih zdravila Corbilta in drugih zdravil za zdravljenje Parkinsonove bolezni.
- Patients with chronic wide-angle glaucoma may be treated with Corbilta with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
- Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Corbilta, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.
At the initiation, Corbilta should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used.
Ob uvedbi zdravljenja je treba zdravilo Corbilta prilagoditi tako, da kar najbolj odgovarja skupnemu do sedaj uporabljanemu dnevnemu odmerku levodope.
For adults and elderly: - Your doctor will tell you exactly how many tablets of Corbilta to take each day.
Za odrasle in starejše: - Vaš zdravnik vam bo povedal, koliko tablet zdravila Corbilta morate vzeti vsak dan. - Tableta ni namenjena za deljenje ali drobljenje na manjše koščke.
Do not take Corbilta if you:
Ne jemljite zdravila Corbilta:
Therefore Corbilta should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension.
Zato je potrebna previdnost pri dajanju zdravila Corbilta bolnikom, ki jemljejo druga zdravila, ki lahko povzročajo ortostatsko hipotenzijo.
Patients taking these medicinal products with Corbilta should be carefully observed for loss of therapeutic response.
Bolnike, ki jemljejo ta zdravila poleg zdravila Corbilta, je treba skrbno spremljati zaradi morebitnega zmanjšanja terapevtskega odgovora.
Patients should be instructed to take only one Corbilta tablet per dose administration.
Bolnikom je treba razložiti, da naj ob vsakem odmerku vzamejo samo eno tableto zdravila Corbilta.
However, a direct switch from levodopa/DDC inhibitor to Corbilta is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg.
Neposreden prehod z levodope/zaviralcev DDK na zdravilo Corbilta pa ni priporočljiv pri bolnikih z diskinezijo ali pri tistih z dnevnim odmerkom levodope nad 800 mg.
Elderly: No dose adjustment of Corbilta is required for elderly.
Starejši: Prilagajanje odmerka pri starejših ni potrebno.
If other levodopa products are used concomitantly with a Corbilta tablet, the maximum dose recommendations should be followed.
Če se sočasno s tabletami zdravila Corbilta uporabljajo druga zdravila z levodopo, je treba upoštevati priporočila o največjem dovoljenem odmerjanju.
Do not stop taking Corbilta unless your doctor tells you to.
Ne prenehajte z jemanjem zdravila Corbilta razen po navodilih zdravnika.
Corbilta is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions) caused by other medicines.
Zdravilo Corbilta se ne priporoča za zdravljenje ekstrapiramidnih simptomov (npr. nehotnih gibov, tremorja, otrdelosti mišic in mišičnih kontrakcij), ki jih povzročajo druga zdravila.
The most frequently reported adverse reactions with Corbilta are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients.
Najpogostejši neželeni učinki, o katerih so poročali pri zdravilu Corbilta, so diskinezija, ki se pojavi pri približno 19 % bolnikov; gastrointestinalni simptomi vključno z navzeo in drisko, ki se pojavijo pri 15 % oz. 12 % bolnikov, bolečina mišic, mišično-skeletna bolečina in bolečina vezivnega tkiva, ki se pojavi pri približno 12 % bolnikov; neškodljivo rdečkastorjavkasto obarvanje urina (kromaturija), ki se pojavi pri približno 10 % bolnikov.
How to transfer patients not currently treated with entacapone to Corbilta
Kako preusmeriti bolnike, ki trenutno ne prejemajo entakapona, na zdravilo Corbilta
The evidence of the therapeutic effects of Corbilta is based on two phase III double-blind studies, in which 376 Parkinson's disease patients with end-of-dose motor fluctuations received either entacapone or placebo with each levodopa/DDC inhibitor dose.
Dokazi o terapevtskih učinkih zdravila Corbilta temeljijo na dveh dvojno slepih raziskavah III. faze, v katerih je 376 bolnikov s Parkinsonovo boleznijo in motoričnimi fluktuacijami na koncu odmernega obdobja ob vsakem odmerku levodope/zaviralca DDK prejemalo bodisi entakapon ali placebo.
Due to entacapone's affinity to cytochrome P450 2C9 in vitro (see section 5.2), Corbilta may potentially interfere with active substances whose metabolism is dependent on this isoenzyme, such as S-warfarin.
Ker ima entakapon afiniteto za citokrom P450 2C9 in vitro (glejte poglavje 5.2), lahko zdravilo Corbilta potencialno vpliva na delovanje učinkovin katerih presnova je odvisna od tega izoencima, kot je to S-varfarin.
If you take more Corbilta than you should
Če ste vzeli večji odmerek zdravila Corbilta, kot bi smeli
If you forget to take Corbilta
Če ste pozabili vzeti zdravilo Corbilta
Corbilta may make it harder for you to digest iron.
Zaradi zdravila Corbilta boste morda težje presnavljali železo.
Patients being treated with Corbilta and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).
Bolnikom, ki se zdravijo z zdravilom Corbilta in navajajo pojav zaspanosti in nenadnega spanca, je treba odsvetovati da vozijo ali se udejstvujejo v dejavnostih, pri katerih lahko zaradi zmanjšane pozornosti sebe ali druge izpostavljajo nevarnosti resne poškodbe ali smrti (npr. upravljanje strojev), vse dokler te epizode ne minejo (glejte poglavje 4.4).
If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines') - notice that uncontrolled movements begin or get worse after you started to take Corbilta.
Če se vam to zgodi, ne vozite in ne upravljajte strojev (glejte tudi poglavje »Vpliv na sposobnost upravljanja vozil in strojev«); - potem, ko ste začeli jemati zdravilo Corbilta, pojavijo nekontrolirani gibi, ali se ti pojavi poslabšajo.
c. When initiating Corbilta in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Corbilta should be started in the next morning.
c. Ko se zdravljenje z zdravilom Corbilta uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Corbilta.
Because the effects of Corbilta tablets are equivalent with entacapone 200 mg tablet administered concomitantly with the commercially available standard release carbidopa/levodopa preparations in corresponding doses these results are applicable to describe the effects of Corbilta as well.
Ker so učinki tablet zdravila Corbilta enaki kot pri tabletah entakapona 200 mg, uporabljenih sočasno z zdravili karbidope/levodope s standardnim sproščanjem v odgovarjajočih odmerkih, so ti rezultati uporabni tudi za prikaz učinkov zdravila Corbilta.
Management of acute overdose with Corbilta therapy is similar to acute overdose with levodopa.
Ukrepi pri akutnem prevelikem odmerjanju zdravila Corbilta so podobni kot pri akutnem prevelikem odmerjanju levodope.
Not known (cannot be estimated from the available data) Craving for large doses of Corbilta in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome.
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) Potreba po visokih odmerkih zdravila Corbilta, ki presegajo odmerek, ustrezen za obvladovanje motoričnih simptomov, ki se imenuje sindrom motene regulacije dopamina.
If you suddenly stop taking of Corbilta and other antiparkinsonian medicines it may result in unwanted side effects.
Če boste nenadno prenehali jemati tablete zdravila Corbilta in druge antiparkinsonike, lahko doživite neželene učinke.
If you stop taking Corbilta
Če ste prenehali jemati zdravilo Corbilta
What Corbilta looks like and contents of the pack
Izgled zdravila Corbilta in vsebina pakiranja
The possibility that the patient has taken other active substances in addition to Corbilta should be taken into consideration.
Upoštevati je treba možnost, da je bolnik vzel poleg zdravila Corbilta še druga zdravila.
Discontinuation of Corbilta therapy: If Corbilta treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is transferred to levodopa/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.
Prekinitev zdravljenja z zdravilom Corbilta: Če je zdravljenje z zdravilom Corbilta (levodopa/karbidopa/entakapon) prekinjeno, bolnik pa namesto tega začne prejemati terapijo z levodopo/zaviralci DDK brez entakapona, je treba za dosego zadovoljive ravni obvladovanja parkinsonskih simptomov prilagoditi odmerjanje drugih antiparkinsonikov, zlasti levodope.
How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Corbilta a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Corbilta tablet strengths can be directly transferred to corresponding Corbilta tablets.
Kako preusmeriti bolnike, ki prejemajo levodopo/zaviralce DDK (karbidopo ali benzerazid) in entakapon tablete na zdravilo Corbilta a. Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Corbilta, lahko neposredno preidejo na uporabo tablet zdravila Corbilta.
Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Corbilta although no cases have been identified from the clinical trial data.
Pri zdravilu Corbilta se lahko pojavi huda oblika hepatitisa s pretežno holestatskimi značilnostmi, rabdomioliza in nevroleptični maligni sindrom, čeprav v podatkih s kliničnega preskušanja niso opredelili nobenega primera.
The effects of Corbilta may be weakened by certain medicines.
Nekatera zdravila lahko oslabijo učinek zdravila Corbilta.